Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Abraham Jacob

Showing results (151-160 of 155) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 155 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2020
ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic LeukemiaPaolo Ghia, Andrzej Pluta, Malgorzata Wach, et al.
American Journal of Medical Genetics. Part A|December 6, 2011
Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2Jaishri O Blakeley, D Gareth Evans, John Adler, et al.
Emerging Infectious Diseases|June 12, 2023
Sensitivity to Neutralizing Antibodies and Resistance to Type I Interferons in SARS-CoV-2 R.1 Lineage Variants, CanadaRajesh Abraham Jacob, Ali Zhang, Hannah O Ajoge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2009
Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2D Gareth Evans, Michel Kalamarides, Kim Hunter-Schaedle, et al.
Iscience|May 3, 2021
Experimental and natural evidence of SARS-CoV-2-infection-induced activation of type I interferon responsesArinjay Banerjee, Nader El-Sayes, Patrick Budylowski, et al.
Pageof 16

Showing results (151-160 of 155) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 155 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2020
ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic LeukemiaPaolo Ghia, Andrzej Pluta, Malgorzata Wach, et al.
American Journal of Medical Genetics. Part A|December 6, 2011
Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2Jaishri O Blakeley, D Gareth Evans, John Adler, et al.
Emerging Infectious Diseases|June 12, 2023
Sensitivity to Neutralizing Antibodies and Resistance to Type I Interferons in SARS-CoV-2 R.1 Lineage Variants, CanadaRajesh Abraham Jacob, Ali Zhang, Hannah O Ajoge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2009
Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2D Gareth Evans, Michel Kalamarides, Kim Hunter-Schaedle, et al.
Iscience|May 3, 2021
Experimental and natural evidence of SARS-CoV-2-infection-induced activation of type I interferon responsesArinjay Banerjee, Nader El-Sayes, Patrick Budylowski, et al.
Pageof 16